- Home
- ANGH vs AKTX Comparison
ANGH vs AKTX Comparison
Compare ANGH & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- AKTX
- Stock Information
- Founded
- ANGH 2012
- AKTX N/A
- Country
- ANGH United Arab Emirates
- AKTX United States
- Employees
- ANGH N/A
- AKTX N/A
- Industry
- ANGH Telecommunications Equipment
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- AKTX Health Care
- Exchange
- ANGH Nasdaq
- AKTX Nasdaq
- Market Cap
- ANGH 32.1M
- AKTX 35.7M
- IPO Year
- ANGH N/A
- AKTX N/A
- Fundamental
- Price
- ANGH $0.45
- AKTX $1.12
- Analyst Decision
- ANGH
- AKTX Strong Buy
- Analyst Count
- ANGH 0
- AKTX 1
- Target Price
- ANGH N/A
- AKTX $5.00
- AVG Volume (30 Days)
- ANGH 195.6K
- AKTX 20.5K
- Earning Date
- ANGH 08-05-2025
- AKTX 08-18-2025
- Dividend Yield
- ANGH N/A
- AKTX N/A
- EPS Growth
- ANGH N/A
- AKTX N/A
- EPS
- ANGH N/A
- AKTX N/A
- Revenue
- ANGH $78,093,405.00
- AKTX N/A
- Revenue This Year
- ANGH N/A
- AKTX N/A
- Revenue Next Year
- ANGH N/A
- AKTX N/A
- P/E Ratio
- ANGH N/A
- AKTX N/A
- Revenue Growth
- ANGH 88.72
- AKTX N/A
- 52 Week Low
- ANGH $0.42
- AKTX $0.85
- 52 Week High
- ANGH $1.01
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ANGH 42.31
- AKTX 44.73
- Support Level
- ANGH $0.44
- AKTX $1.08
- Resistance Level
- ANGH $0.51
- AKTX $1.15
- Average True Range (ATR)
- ANGH 0.05
- AKTX 0.03
- MACD
- ANGH -0.00
- AKTX 0.00
- Stochastic Oscillator
- ANGH 6.78
- AKTX 57.14
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.